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Summary In 65 patients with systemic breast cancer, a biochemical response index using three tumour
markers in combination, carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3) and erthrocyte
sedimentation rate (ESR), allowed objective biochemical assessment of response to endocrine therapy. Changes
in these three markers at 2, 4 and 6 months showed a highly significant correlation with UICC assessed
response at 6 months. At 4 months, changes in these three markers resulted in a selectivity of 93%, with a
sensitivity of 92% and a specificity of 82%. Survival of groups of patients assessed biochemically or by UICC
criteria for non-progression or progression showed no significant difference.
The advantages of the biochemical assessment are that it is objective and reproducible. The assessment gives
similar information to the UICC assessment but can be carried out earlier. Changes in the three markers
appears to reflect the dynamics of change in tumour mass in response to systemic therapy in contrast to the
UICC criteria which reflect structural change.
Endocrine therapy for advanced breast cancer was first intro-
duced by a surgeon in Scotland in 1896 (Beatson, 1896) yet
we still lack truly objective criteria by which to assess
therapeutic response. Even the criteria most widely used at
present, i.e. International Union Against Cancer (UICC)
criteria, acknowledge their inherent subjectivity by requiring
external review of response data. More recently clinicians
have investigated the potential role of tumour markers both
in the diagnosis of breast cancer and in measuring response
to therapy.
There is no single, ideal tumour marker for breast cancer.
Combinations of tumour markers, including carcinoem-
bryonic antigen (CEA), have been investigated to increase the
sensitivity of detecting metastases by biological markers
(Franchimont et al., 1976; Coombes et al., 1977a; Coombes
et al., 1977b; Cowen et al., 1978; Cove et al., 1979; Coombes
et al., 1981; Bezwoda et al., 1981). A much smaller number
of studies have reported on the use of CEA in combination
with other biological markers in measuring response (Woo et
al., 1978; Waalkes et al., 1978; Haagensen et al., 1978; Silva
et al., 1982).
Following the discovery of monoclonal antibodies by
Kohler and Milstein (1975), monoclonal antibodies have
been raised to a number of breast cancer associated antigens.
Serum CEA has been examined in combination with a
number of monoclonal antibodies raised to tumour
associated antigens - e.g. MAM-6 antigen, 115D8 (Hilkens et
al., 1987), CA15-3 antigen (Hayes et al., 1986; Fujino et al.,
1986; Pons-Anicet et al., 1987; Kallioniemi et al., 1988; Ton-
dini et al., 1988; Delarue et al., 1988) and mammary serum
antigen (MSA) (Stacker et al., 1988). Other newer mono-
clonal antibodies have been reported such as MCA (Stahli et
al., 1989), CA 549 (Bray et al., 1989) and CA M26 and CA
M29 (van Ramp et al., 1989). However to date the value of
these newer monoclonal antibodies either in combination
with 'or compared to CEA has not been reported.
In Nottingham we have previously shown in a retrospec-
tive analysis (Williams et al., 1990) and prospectively
confirmed (Robertson et al., 1990), that changes in serum
CEA and ESR (erythrocyte sedimentation rate) individually
correlate with therapeutic response in patients with meta-
static breast cancer. We have also evaluated four new serum
tumour markers identified by monoclonal antibodies raised
either to milk fat globule membrane fractions (HMFG1 and
HMFG2) or human breast cancer tissue (CA15-3 and
NCRC-11); only changes in serum CA15-3 correlated with
therapeutic response (Robertson et al., 1990).
This present study combined the three serum markers
showing independent correlation with response (CEA, CA15-
3 and ESR) into one index and compared the results with
UICC assessed response.
Patients
Over a 12 month period 85 consecutive patients with newly
diagnosed systemic breast cancer presented to our unit. Six-
teen patients presented for the first time with stage IV disease
while the remaining 69 patients had recurrent metastatic
disease having previously been treated for primary breast
cancer (Stage I (n = 14), Stage II (n = 44), Stage III (n = 9)
and Stage unknown (n = 2)). The mean age (± SD) (years)
of the patients was 60.52 (± 12.22) years. Fourteen patients
were premenopausal and 71 postmenopausal at the time of
diagnosis of metastatic disease. Patients were assessed before
treatment and at two monthly intervals by clinical examina-
tion, routine haematology and biochemistry, biological
markers and skeletal survey. Other investigations (e.g. CT
scan) were performed if clinically indicated. The site of initial
metastatic disease in these 85 patients was bone (n = 33),
lung (n = 27), bone and lung (n = 11) and viscera (n = 14).
Oestrogen receptor (ER) and progesterone receptor (PgR)
concentration was measured on the primary tumour tissue
using either the dextran charcoal method or enzyme
immunoassays; both methods have previously been reported
by our unit (Nicholson et al., 1981; Nicholson et al., 1986).
With both assays values of < 5 fmoles mg-' cytosol protein
were regarded as negative. Thirty tumours were ER positive
and 23 ER negative. In 32 patients the ER status of the
primary tumour was unknown. For PgR 22 tumours were
positive, 29 were negative and in 34 PgR status was not
known.
All patients received systemic endocrine therapy. Initial
therapy for 14 premenopausal patients was the LHRH agon-
ist goserelin, Zoladex (ICI Pharmaceuticals), 3.6 mg monthly
by subcutaneous injection and the anti-oestrogen tamoxifen,
Nolvadex (ICI Pharmaceuticals), 20 mg b.d. Postmenopausal
patients were treated either with tamoxifen 20 mg b.d.
(n = 69) or the synthetic progestagen megestrol acetate
(Megace, Bristol Myers) 160 mg b.d. (n = 2).
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It is conventional when assessing response in advanced
breast cancer to exclude from the analysis of response
patients with a life expectancy of <3 months at presentation
and patients with systemic disease unassessable by the Inter-
national Union Against Cancer (UICC) criteria (Hayward et
al., 1977). Three patients were unassessable for response by
UICC criteria. Seventeen patients who died within 3 months
of starting endocrine therapy all had UICC assessable
disease; the main site of disease at presentation being liver
(n = 7), lung/pleura (n = 5), bone and lung (n = 1), bone
(n = 2) or lymph nodes (n = 2). Direct comparison between
changes in tumour marker concentrations and UICC assessed
response has therefore been made in patients who survived
>3 months (n = 65).
Methods
Assessment ofresponse
Clinical assessment of response Patients with metastatic
breast cancer were assessed by UICC criteria prior to com-
mencing anticancer therapy and after 2, 4 and 6 months
therapy or between these times if clinically indicated. As
recommended by the British Breast Group (1974) patients
were classified as showing complete or partial response or
static disease (no change) only where the minimum duration
of response or static disease was 6 months. Assessment of
response in all patients was externally reviewed. Patients with
static disease for at least 6 months on endocrine therapy have
similar survival to patients with responding disease, both
groups surviving significantly longer than patients with pro-
gressive disease by 6 months (Howell et al., 1988; Robertson
et al., 1989). In analysing the correlation between bio-
chemical marker movement after 2, 4 or 6 months therapy
and UICC assessed response we combined the categories of
complete response (CR), partial response (PR) and static
disease (SD) into 'non-progressive' disease group and com-
pared this with the group of patients showing progression.
Biochemical assessment of response Biochemical response to
therapy in patients with metastatic breast cancer is assessed
in the same manner for all serum markers studied in this unit
- i.e. any change in marker while the patient is on therapy is
related to the pre-treatment baseline value of the marker and
the interassay coefficient of variation (CV) of the marker
(10% for all three markers in this study). A cut-off level for
each individual marker of the mean ± 2 SD of the normal
control group was calculated. Patients who never showed an
elevation of the marker above this level were regarded as
biochemically unassessable for that particular marker.
Patients who started with an initially elevated value which
fell to below the cut-off level or patients with an initial value
above the cut-off level which subsequently decreased by more
than the interassay CV (10%) for that particular marker were
regarded as showing a decreasing marker level indicative of
'biochemical response'. As in our previous reports (Williams
et al., 1990; Robertson et al., 1990) CEA and ESR were
scored - 2 and -I respectively. CA15-3 was scored the same
as CEA (i.e. - 2). Patients with an initial pretreatment value
below the cut-off level which subsequently rose above the
cut-off level or patients with an initial value above the cut-off
level which subsequently increased above the interassay CV
(10%) for that particular marker were regarded as showing
an increasing marker level indicative of 'biochemical progres-
sion' (all markers scored + 2). Patients with levels which
started and remained above cut-off but which moved by less
than the interassay CV (10%) were regarded as
'biochemically stable' and scored + 1.
Change in the concentration of each serum marker was
scored as summarised in Table I.
Since a 10% change in marker concentration may seem
small, the data were also analysed using a 20% change in
each marker as significant to see if this made any difference
to the results. The scores for each individual marker were
added together to give the response index score.
Statistical analyses
Data were analysed using the statistical package SPSSX-21
(SPSS, 1986). Analysis of variance and Scheffe range testing
were used to compare marker values for stage of disease.
Chi-squared analysis with Yates correction where appropri-
ate and Fisher's Exact test were used to compare frequencies
of integers between two variables. In accordance with con-
vention in all analysis P <0.05 was taken as significant.
Serum markers
Venous blood was withdrawn and allowed to clot, centri-
fuged and serum removed and aliquoted before being stored
Table II CEA and ESR vs UICC response (Marker change
> ± 10%)
Pre-treatment CEA and ESR
Stage IV disease
a. Versus 2 months (Markers measured (n) = 63;
Markersassessable (n) = 51)
Index score
<0 >0
UIcc
Response 13
Static 9
Progression 12
X2 = 8.248; 1 d.f.; P = 0.0041
2
1
14
b. Versus 4months (Markersmeasured (n) = 57;
Markersassessable (n) = 45)
Index score
<0 >0
UIcc
Response 13
Static 8
Progression 10
X2 = 8.994; 1 d.f.; P = 0.0027
2
0
12
c. Versus 6months (Markers measured (n) = 58;
Markers assessable (n) = 50)
Index score :0 >0
UIcc
Response 14 3
Static 9 1
Progression 6 17
X2 = 15.464; 1 d.f.; P = 0.0001
(Responseandstaticcombined vsprogression)
Table I Scores for changes in marker concentrations
Upper
limit Normal Decrease Stable Increase
of normal limits (->10%) (±<10%) (+>10%)
CEA 6ngml 0 -2 +l +2
CA15-3 3Uml 0 -2 +1 +2
ESR 20mmh 0 -1 +1 +2MEASUREMENT OF THERAPEUTIC RESPONSE IN BREAST CANCER 759
Table lIb CEA and ESR vs UICC response (Marker swing
> ± 20%)
Pre-treatment CEA and ESR
Stage IV disease
a. Versus 2months(Markersmeasured(n) = 63;
Markers assessable (n) = 51)
Index score
.0 >0
UICC
Response 13
Static 7
Progression 13
X2 = 3.795; 1 d.f.; P = 0.0514
2
3
13
b. Versus 4months (Markersmeasured(n) = 57;
Markers assessable (n) = 45)
Index score
.0 >0
UICC
Response 13
Static 8
Progression 10
X2 = 8.994; 1 d.f.; P = 0.0027
2
0
12
c. Versus 6months (Markers measured(n) = 58;
Markers assessable (n) = 50)
Index score
.0 >0
UICC
Response 13 4
Static 9 1
Progression 6 17
X =13.301;1d.f.;P=0.0003
(Responseandstaticcombined vsprogression)
Table IIIb CA15-3 and CEA vs UICC response (Marker swing
> ± 20%)
Pre-treatment CEA and CA15-3
Stage IV disease
a. Versus 2months(Markersmeasured(n) = 63;
Markers assessable(n) = 55)
Index score
.0 >0
UICC
Response 11
Static 5
Progression 9
X2= 5.061; 1 d.f.; P = 0.0245
5
4
21
b. Versus4months(Markersmeasured(n) = 57;
Markers assessable(n) = 47)
Index score
.0 >0
UICC
Response 12
Static 4
Progression 5
X2 = 15.171; 1 d.f.; P <0.0001
2
2
22
c. Versus6months (Markersmeasured (n) = 58;
Markers assessable (n) = 47)
Index score
.0 >0
UICC
Response 12 3
Static 6 2
Progression 5 19
X2 = 13.287; 1 d.f.; P = 0.0003
(Responseandstaticcombined vsprogression)
initially at - 20°C and subsequently transferred to storage at
- 70°C. All samples were assayed blind of clinical inform-
ation on aliquots thawed once only. Marker concentrations
in each specimen were always measured in duplicate.
CA15-3 CA15-3 was measured using the commercially
available CIS ELSA kit (CIS, High Wycombe, UK). Intra-
Table III CA15-3 and CEA vs UICC response (Marker change
> ± 10%)
Pre-treatment CEA and CA15-3
Stage IV disease
a. Versus 2months(Markers measured (n) = 63;
Markers assessable (n) = 55)
Index score
.0 >0
UICC
Response 11
Static 5
Progression 9
x2 = 5.061; 1 d.f.; P = 0.0245
5
4
21
b. Versus 4months (Markers measured (n) = 57;
Markers assessable (n) = 47)
Index score
.0 >0
UICC
Response 12 2
Static 5 1
Progression 5 22
X2 = 17.813; 1 d.f.; P <0.0001
c. Versus 6months (Markers measured (n) = 58;
Markers assessable (n) = 47)
Indexscore
.0 >0
UIcCC
Response 13 2
Static 6 2
Progression 5 19
X2 = 15.549; I d.f.; P = 0.0001
(Responseandstaticcombined vsprogression)
assay variation was estimated using sera containing low
(mean 7.8 Uml-1), medium (mean 30 U ml-') and high
values (mean 723 U ml-') of CA15-3: the C.Vs were 13.2%,
5.0% and 3.1% respectively. The inter-assay C.V. estimated
using the medium value of CA15-3 was 9.2%.
Carcinoembryonic antigen (CEA) CEA was measured in
aliquots of serum using the commercially available CIS
ELSA kit (CIS, UK). The intra- and inter-assay coefficients
of variation (CVs) were 6.9% and 7.1% respectively.
Erythrocyte sedimentation rate (ESR) Two ml of freshly
aspirated blood was placed in a tube containing EDTA. ESR
was measured by the Westergen technique.
Results
Of the 65 patients who were both assessable for response and
survived for >3 months three (5%) showed a complete
response to systemic endocrine therapy, 19 (29%) showed a
partial response, and 10 (15%) had static disease. Thirty-
three patients (51%) showed progression of disease within 6
months. Therefore 49% of patients had non-progressive
disease (response and static) for a minimum of 6 months and
51% patients progressed within 6 months of therapy.
UICC assessed response was compared with the bio-
chemical index score using - (1) CEA and ESR together, (2)
CEA and CA15-3 in combination as omission of ESR would
allow the index to be calculated from serum samples alone
(fresh or frozen) and (3) CEA, CA15-3 and ESR. The
previously set cut-off levels (see Table I) were used for all
three markers (i.e. CEA 6 ng ml', CA15-3 33 Uml-' and
ESR 20 mm h-'). As noted above a change in a marker from
the baseline value of > ± 10% (or > ± 20%) was regarded
as significant. Scores for each individual marker were added
together to give a 'biochemical response score'.760 J.F.R. ROBERTSON et al.
CEA and ESR
Changes in CEA and ESR in combination showed a highly
significant correlation with UICC response at 2, 4 and 6
months (Table II). Reanalysis using a change in the baseline
value of > ± 20% as significant gave a similar result at 2, 4
and 6 months (Table IIb).
CEA and CA15-3
Changes in serum CEA and CA15-3 in combination showed
a highly significant correlation with UICC response at 2, 4
and 6 months (Table III). Reanalysis using a change in the
baseline value of > ± 20% as significant gave a similar result
at 2, 4 and 6 months (Table IIIb).
CA15-3, CEA and ESR
Using CA15-3, CEA and ESR in combination the
biochemical score at 2, 4 and 6 months correlated
significantly with UICC assessed response at 6 months (Table
IV). The analysis was repeated taking a change from the
baseline of > ± 20% as significant. The results are shown in
Table V. There was no difference in the correlation with the
UICC response whether a change in each marker of
> ± 10% (Table IV) or > ± 20% (Table V) was used in
calculating the biochemical score.
Correlation between the biochemical response score and
UICC assessed response appeared better using the
biochemical scores at 4 or 6 months than at 2 months.
However even comparing the 4 month biochemical assess-
ment with the UICC assessed response at 6 months there was
still seven patients out of 53 who were classified differently by
the two methods as assessment (Table IV). To identify if
either method of assessment was significantly different from
the other, the assessments of response by UICC at 6 months
and biochemical score at 4 months were plotted against
survival from commencing systemic therapy. Figure 1 show-
ing survival by the four recognised UICC criteria (complete
response (CR), partial response (PR), static disease (SD) or
progressive disease (PD)) confirmed that in this group,
patients with static disease at 6 months had similar survival
Table IV CEA, CA15-3 and ESR vs UICC response (Marker
change > ± 10%)
Pre-treatment CEA, ESR and CA15-3
Stage IV disease
a. Versus 2months (Markersmeasured (n) = 63;
Markers assessable(n) = 60)
Index score
(0 >0
UICC
Response 15
Static 6
Progression 10
X2 = 8.134; I d.f.; P = 0.0043
4
4
21
b. Versus 4months (Markers measured (n) = 57;
Markers assessable (n) = 53)
Index score
(0 >0
UICc
Response 16
Static 8
Progression 5
XI = 26.204; 1 d.f.; P <0.0001
2
0
22
c. Versus 6months (Markers measured (n) = 58;
Markers assessable (n) = 54)
Index score
(0 >0
UICC
Response 17 2
Static 9 1
Progression 6 19
X2 = 21.329; 1 d.f.; P <0.0001
(Responseandstaticcombined vsprogression)
Table V CEA, CA15-3 and ESR vs UICC response (Marker change
> ± 20%)
Pre-treatment CEA, ESR and CA15-3
Stage IV disease
a. Versus 2months(Markersmeasured(n) = 63;
Markersassessable (n) = 60)
Index score
(0 >0
UICC
Response 15
Static 5
Progression 10
X2= 6.674; 1 d.f.; P = 0.0098
4
5
21
b. Versus4months(Markersmeasured (n) = 57;
Markersassessable(n) = 53)
Index score
(0 >0
UICC
Response 16 2
Static 8 0
Progression 5 22
X2= 26.204; 1 d.f.; P <0.0001
c. Versus 6months (Markersmeasured (n) = 58;
Markersassessable (n) = 54)
Index score
(0 >0
UICC
Response 16 3
Static 9 1
Progression 6 19
X2= 18.780; 1 d.f.; P <0.0001
(Responseandstaticcombined vsprogression)
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Figure 1 Survival from Initial Systemic Therapy by UICC
Assessment of Response to Initial Therapy. - *- CR, --O--
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to patients showing partial response at 6 months. The
number of deaths in each of the UICC categories were 0 out
of three patients with complete response, one out of 19
patients with partial response, one out of ten patients with
static disease and 15 out of 33 patients with progressive
disease.
Since the survival of patients with partial response and
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_
1MEASUREMENT OF THERAPEUTIC RESPONSE IN BREAST CANCER 761
Table VI Number of patients biochemically assessable by serum
markers
Pre-treatment concentration
Stage IV disease
a. Versus2months(Markers measured(n) = 63)
CEA
Marker CEA ESR CA15-3 ESR
(n) 29 39 49 51
x2=54.06; 5 d.f.; P <0.001
b. Versus4months(Markersmeasured(n) =
CEA
Marker CEA ESR CA15-3 ESR
0 3 6 9 12 15
Time (months)
26 26 26 20 14 2
(n)
I 18 21
29 29 21 14 2
X2=0.21 1 d.f. p>0.05
Figure 2 Survival by UICC criteria CR + PR + STATIC at 6
months compared with biochemical scores 0 at 4 months using
CEA, CA15-3 and ESR. 0 CR + PR + STATIC
(UICC), ---O--- SCORE K,0 (BIOCHEMICAL).
28 33 40 45
X2 =37.36; 5d.f.; P<0.001
c. Versus 6months(Markers measured(n) =
CEA
Marker CEA ESR CA15-3 ESR
(n) 28 37 41 50
x2 =40.25; 5d.f.; P <0.001
CEA
CEA CA15-3
CA15-3 ESR
55 60
57)
CEA
CEA CA15-3
CA15-3 ESR
47 53
58)
CEA
CEA CA15-3
CA15-3 ESR
47 54
static disease was similar (Figure 1) CR + PR + SD were
combined into one larger group and comparison made
between non-progressive and progressive disease by each
method of assessment. The survival of UICC non-progressors
(CR + PR + STATIC) was compared with the biochemical
non-progressors (score <0) by log rank analysis and the
results expressed as a x2 value (Figure 2). The survival of
UICC progressors was compared with the biochemical pro-
gressors (score >0) (Figure 3). Survival was similar between
the two methods of assessment of non-progressive and pro-
gressive disease.
Table VI shows the number of patients UICC assessable
who were also biochemically assessable using CEA, ESR or
CA15-3 individually or in various combinations. At 2, 4 and
6 months there was a significant increase in the number of
patients biochemically assessable as the number of markers
increased. In particular, significantly more patients were
assessable using CEA/CA15-3/ESR than using only CEA/
0
L-
C/)
Time (months)
-27 27
--- 24 24
26 16 10 6
23 15 10 6
2
2
X= 0.0003 1 d.f. p>0.05
Figure 3 Survival by UICC Progression at 6 months compared
with biochemical score >0 at 4 months using CEA, CA15-3 and
ESR. PROGRESSION (UICC), ---O--- SCORE
>0 (BIOCHEMICAL).
CA15-3. Using the three markers in combination 93% of
patients with systemic breast cancer were biochemically
assessable.
Selectivity, sensitivity, specificity and overall accuracy were
slightly different for each combination of markers, CEA/ ESR, CEA/CA15-3 and CEA/CA15-3/ESR, assessed at 2, 4
or 6 months. Selectivity was defined as the number of
patients who were biochemically assessable by a particular
combination of markers over the total number of patients in
whom these markers were measured. Sensitivity, specificity and accuracy of each particular combination of markers in
assessing response was then calculated from those patients who were assessable both by markers and UICC. Sensitivity
was the number ofpatients in whom biochemical and UICC
assessment ofnon-progression (response + static disease) cor-
related over the number of patients assessed as non-
progressors by UICC. Specificity was the number ofpatients in whom biochemical and UICC assessment of progression correlated over the number of patients assessed as progres-
sors by UICC. Overall accuracy was defined as the number
of patients where biochemical and UICC assessment (non-
progression and progression) agreed over the total number of
patients assessed by both methods. Results are shown in
Table VII. Selectivity, sensitivity, specificity and accuracy
were highest using the CEA/CA15-3/ESR combination;
assessment at 4 months was better than at either 2 or 6
months.
Discussion
Recent reports have questioned the value of CEA in addition
to CA15-3 which was individually the more sensitive marker
both in diagnosis of systemic disease (Hayes et al., 1986; Delarue et al., 1988; Tondini et al., 1988) and in assessing
response to therapy (Tondini et al., 1988). It has been sug- gested that CEA added nothing to CA15-3 alone neither in
the diagnosis of metastatic disease (Delarue et al., 1988) nor
in monitoring response to therapy (Tondini et al., 1988). We
have shown that by changing the marker combination and by increasing the number of markers, the number of patients who become 'biochemically' assessable increased significantly
(Tables VI and VII).
If patients showed elevation of any of the three markers, the biochemical response index score correlated very well with
UICC assessed response whatever marker or combination of
markers were assessable. There was only slight differences in
Iu
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l762 J.F.R. ROBERTSON et al.
Table VII Selectivity, sensitivity, specificity and accuracy of different combination of markers
Marker Months
combination assessed % Selectivity % Sensitivity % Specificity % Accuracy
CEA/ESR 2 81 88 54 71
4 79 92 54 73
6 86 85 74 80
CEA/CA15-3 2 87 64 70 67
4 83 85 82 83
6 81 83 79 81
CEA/CA15-3/ESR 2 95 72 68 70
4 93 92 82 87
6 93 90 76 83
the overall accuracy for each marker combination (Table
VII). The improvement produced by combining markers was
in increasing the number of patients who became bio-
chemically assessable (Table VI). Although the number of
patients biochemically assessable was not statistically higher
using CEA and CA15-3 in combination against CA15-3
alone (X2 = 2.37; 1 d.f.; P >0.05), similar comparison
between CEA, CA15-3 and ESR vs CA15-3 alone (X2= 8.41;
1 d.f.; P <0.01) did show a significant increase in the
number of patients biochemically assessable. The overall x2
value shown (Table VI) confirmed that the increase in the
number of biochemically assessable patients by combining
the markers was statistically significant (X2 = 37.36; 5 d.f.;
P <0.001). Previous reports all show an increase (though
not significant) in the number of patients assessable using
CEA and CA15-3 compared to CA15-3 alone: this trend in
all the reported studies, together with the results shown in
this study suggest that lack of numbers is the most likely
explanation why this consistent increase in the number of
patients assessable by CEA and CA15-3 in combination vs
CA15-3 alone has not been shown to reach statistical
significance in any individual study. In this prospective study,
selectivity, sensitivity and specificity were all highest using the
CEA/CA15-3/ESR combination (Table VII); at 4 months,
selectivity was 93%, sensitivity 92%, specificity 82% and
overall accuracy 87%. The use of this combination of three
tumour markers in patients with systemic breast cancer
appears to provide an assessment of response to endocrine
therapy which gives similar information to the UICC assess-
ment but at an earlier date and is both objective and repro-
ducible.
Changes in the markers reported in this study correlated
with UICC response irrespective of whether the size of the
marker change was 10% or 20% of the baseline values.
Changes in the markers at 2 or 4 months predicted response
at 6 months as assessed by UICC criteria. Changes in the
three markers (CEA, CA15-3 and ESR) appear to reflect the
dynamics ofchange in tumour mass in response to therapy in
contrast to the UICC criteria which reflect structural change.
We have shown assessment by markers would not have been
detrimental to patient survival. On the contrary changing
therapy as a result of increasing marker concentrations
before structural changes are seen may allow the clinician
time to find a therapy which will induce a therapeutic re-
sponse resulting in a consequent improvement in survival.
We are currently testing this hypothesis in a controlled
clinical trial.
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